Pre-made Mavezelimab benchmark antibody ( Whole mAb, anti-LAG3 therapeutic antibody, Anti-CD223 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Mavezelimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Mavezelimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody |
|---|---|
| INN Name | Mavezelimab |
| Target | LAG3 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Merck |
| Conditions Approved | NA |
| Conditions Active | Non-small cell lung cancer,Haematological malignancies,Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | favezelimab |
| Gm Offical Target Name | LAG3 |
| Package |
